6 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 6 |
| Phase 1 | 1 | Terminated 1 |
Follow Stage IIIC Melanoma: new trials by email Literature Review of Stage IIIC Melanoma trials Research Report on Stage IIIC Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery aldesleukin, ipilimumab, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | CINJRegulatory | 9 | 2014-11-26 | 2023-07-18 |
| Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery dabrafenib, trametinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced) | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 13 | 2013-01-01 | 2017-06-23 |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib Akt inhibitor MK2206, selumetinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2012-01-01 | 2014-06-18 |
| Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery axitinib, laboratory biomarker analysis - Extraocular Extension Melanoma, Metastatic Intraocular Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 25 | 2012-01-01 | 2018-05-09 |
| Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma laboratory biomarker identification and analysis, biopsy, immunohistochemistry/tissue microarrays - Recurrent Melanoma, Stage IIIc Melanoma | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 12 | 2011-10-01 | 2016-05-30 |
| Dinaciclib in Treating Patients With Stage III-IV Melanoma dinaciclib, pharmacological study, laboratory biomarker analysis - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2009-09-01 | 2017-04-04 |
Melanoma (6) · Uveal Melanoma (1)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Neuroendocrine Tumors (6) · Nevi and Melanomas (6) · Skin Diseases (6) · Skin Neoplasms (6) · Skin and Connective Tissue Diseases (6) · Eye Diseases (1) · Eye Neoplasms (1) · Uveal Diseases (1) · Uveal Neoplasms (1)
AZD 6244 (1) · Axitinib (1) · Biopsy (1) · CTLA-4 Antigen (1) · Immunohistochemistry (1) · Interleukin-2 (1) · Ipilimumab (1) · MK 2206 (1) · Mass Spectrometry (1) · aldesleukin (1) · dabrafenib (1) · dinaciclib (1) · trametinib (1)
National Cancer Institute (NCI) (2) · Vanderbilt-Ingram Cancer Center (2) · CINJRegulatory (1) · Roswell Park Cancer Institute (1)
United States (6)
Frank Hodi (1) · Howard Kaufman (1) · Jeffrey Sosman (1) · Jeffrey Sosman, MD (1) · Mark Kelley (1) · Matuesz Opyrchal, MD (1)
N01CM00100 (1), P30CA006516 (1), P30CA016056 (1), P30CA072720 (1), U01CA062490 (1)